Do analysts recommend CALT or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CALT or LWAC?

LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Do analysts rate LWAC or AVLN?

Avalyn Pharma has a consensus target price of $59.00, indicating a potential upside of 112.31%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Avalyn Pharma is more favorable than LightWave Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalyn Pharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20

Which has stronger earnings and valuation, LWAC or AVLN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Avalyn Pharma N/A N/A N/A -$21.83 N/A

Is LWAC or AVLN more profitable?

Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Avalyn Pharma N/A N/A N/A

Does the media prefer LWAC or AVLN?

In the previous week, Avalyn Pharma had 3 more articles in the media than LightWave Acquisition. MarketBeat recorded 6 mentions for Avalyn Pharma and 3 mentions for LightWave Acquisition. LightWave Acquisition's average media sentiment score of 1.84 beat Avalyn Pharma's score of 0.51 indicating that LightWave Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LightWave Acquisition 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Avalyn Pharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LWAC or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, LWAC or AVTE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is LWAC or AVTE more profitable?

LightWave Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts rate ELYM or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, ELYM or LWAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Is ELYM or LWAC more profitable?

LightWave Acquisition's return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% LightWave Acquisition N/A N/A N/A

Do analysts prefer NLTX or LWAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, NLTX or LWAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A LightWave Acquisition N/A N/A N/A N/A N/A

Is NLTX or LWAC more profitable?

LightWave Acquisition's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% LightWave Acquisition N/A N/A N/A

LightWave Acquisition (LWAC) Competitors

$10.27 +0.01 (+0.10%)

As of 04:00 PM Eastern

Compare

LWAC vs. CALT, AVLN, AVTE, ELYM, and NLTX

Should you buy LightWave Acquisition stock or one of its competitors? MarketBeat compares LightWave Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LightWave Acquisition include Calliditas Therapeutics AB (publ) (CALT), Avalyn Pharma (AVLN), Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), and Neoleukin Therapeutics (NLTX).

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, LightWave Acquisition had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for LightWave Acquisition and 0 mentions for Calliditas Therapeutics AB (publ). LightWave Acquisition's average media sentiment score of 1.84 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
LightWave Acquisition	Very Positive

LightWave Acquisition has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. LightWave Acquisition's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
LightWave Acquisition	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

LightWave Acquisition beats Calliditas Therapeutics AB (publ) on 6 of the 9 factors compared between the two stocks.

How does LightWave Acquisition compare to Avalyn Pharma?

LightWave Acquisition (NASDAQ:LWAC) and Avalyn Pharma (NASDAQ:AVLN) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Avalyn Pharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Avalyn Pharma has a consensus target price of $59.00, indicating a potential upside of 112.31%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Avalyn Pharma is more favorable than LightWave Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Avalyn Pharma had 3 more articles in the media than LightWave Acquisition. MarketBeat recorded 6 mentions for Avalyn Pharma and 3 mentions for LightWave Acquisition. LightWave Acquisition's average media sentiment score of 1.84 beat Avalyn Pharma's score of 0.51 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LightWave Acquisition	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Avalyn Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Avalyn Pharma beats LightWave Acquisition on 5 of the 6 factors compared between the two stocks.

How does LightWave Acquisition compare to Aerovate Therapeutics?

LightWave Acquisition (NASDAQ:LWAC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, LightWave Acquisition had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for LightWave Acquisition and 0 mentions for Aerovate Therapeutics. LightWave Acquisition's average media sentiment score of 1.84 beat Aerovate Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
LightWave Acquisition	Very Positive
Aerovate Therapeutics	Neutral

LightWave Acquisition's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

LightWave Acquisition beats Aerovate Therapeutics on 5 of the 5 factors compared between the two stocks.

How does LightWave Acquisition compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, LightWave Acquisition had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for LightWave Acquisition and 0 mentions for Eliem Therapeutics. LightWave Acquisition's average media sentiment score of 1.84 beat Eliem Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
LightWave Acquisition	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LightWave Acquisition's return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
LightWave Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

LightWave Acquisition beats Eliem Therapeutics on 5 of the 7 factors compared between the two stocks.

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, LightWave Acquisition had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for LightWave Acquisition and 0 mentions for Neoleukin Therapeutics. LightWave Acquisition's average media sentiment score of 1.84 beat Neoleukin Therapeutics' score of 0.00 indicating that LightWave Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
LightWave Acquisition	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

LightWave Acquisition's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
LightWave Acquisition	N/A	N/A	N/A

Summary

LightWave Acquisition beats Neoleukin Therapeutics on 5 of the 7 factors compared between the two stocks.

Get LightWave Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LWAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LWAC vs. The Competition

Export

Metric	LightWave Acquisition	Pharmaceutical Preparations Industry	Sector	NASDAQ Exchange
Market Cap	$308.92M	$945.02M	$2.97B	$12.13B
Dividend Yield	N/A	4.84%	15.23%	9.43%
P/E Ratio	N/A	1.52	14.63	23.79
Price / Sales	N/A	103.71	3,103.93	76.37
Price / Cash	N/A	22.05	47.23	46.66
Price / Book	N/A	8.58	11.04	6.10
Net Income	N/A	-$3.26M	-$189.28M	$336.45M
7 Day Performance	0.35%	-0.36%	-0.75%	-2.14%
1 Month Performance	0.39%	-6.22%	-0.32%	-3.31%
1 Year Performance	N/A	26.14%	9.25%	13.49%

LightWave Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LWAC LightWave Acquisition	N/A	$10.27 +0.1%	N/A	N/A	$308.92M	N/A	N/A	N/A	News Coverage Positive News
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
AVLN Avalyn Pharma	3.6978 of 5 stars	$28.30 +10.2%	$59.00 +108.5%	N/A	$1.14B	N/A	N/A	51
AVTE Aerovate Therapeutics	N/A	$20.86 +1.9%	N/A	+142.5%	$604.63M	N/A	N/A	20	High Trading Volume
ELYM Eliem Therapeutics	N/A	$12.70 +1.0%	N/A	+785.5%	$377.85M	N/A	N/A	9	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LWAC) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LightWave Acquisition (LWAC) Competitors

LWAC vs. CALT, AVLN, AVTE, ELYM, and NLTX

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Summary

How does LightWave Acquisition compare to Avalyn Pharma?

Summary

How does LightWave Acquisition compare to Aerovate Therapeutics?

Summary

How does LightWave Acquisition compare to Eliem Therapeutics?

Summary

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LWAC vs. The Competition

LightWave Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LightWave Acquisition (LWAC) Competitors

LWAC vs. CALT, AVLN, AVTE, ELYM, and NLTX

How does LightWave Acquisition compare to Calliditas Therapeutics AB (publ)?

Does the media prefer CALT or LWAC?

Is CALT or LWAC more profitable?

Do analysts recommend CALT or LWAC?

Do insiders and institutionals have more ownership in CALT or LWAC?

Which has higher earnings and valuation, CALT or LWAC?

Summary

How does LightWave Acquisition compare to Avalyn Pharma?

Is LWAC or AVLN more profitable?

Which has stronger earnings and valuation, LWAC or AVLN?

Do analysts rate LWAC or AVLN?

Does the media prefer LWAC or AVLN?

Summary

How does LightWave Acquisition compare to Aerovate Therapeutics?

Which has higher earnings and valuation, LWAC or AVTE?

Does the media prefer LWAC or AVTE?

Is LWAC or AVTE more profitable?

Do analysts rate LWAC or AVTE?

Summary

How does LightWave Acquisition compare to Eliem Therapeutics?

Do insiders and institutionals have more ownership in ELYM or LWAC?

Does the media prefer ELYM or LWAC?

Do analysts rate ELYM or LWAC?

Is ELYM or LWAC more profitable?

Which has preferable valuation and earnings, ELYM or LWAC?

Summary

How does LightWave Acquisition compare to Neoleukin Therapeutics?

Which has stronger valuation and earnings, NLTX or LWAC?

Do insiders and institutionals have more ownership in NLTX or LWAC?

Does the media prefer NLTX or LWAC?

Do analysts prefer NLTX or LWAC?

Is NLTX or LWAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LWAC vs. The Competition

LightWave Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools